lobbying_activities: 2421993

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2421993	51f19d84-0b6f-4b5b-8d24-7f1c487b5ca4	Q1	ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)	1466	ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC)	2020	first_quarter	MED	On February 28, 2020 AACC wrote to the Food and Drug Administration requesting that the agency permit laboratories develop laboratory developed tests to detect COVID-19 without having to obtain an Emergency Use Authorization from the agency. On March 25, 2020 AACC wrote to the Department of Health and Human Services requesting that pathologists and related staff be permitted to work offside during the COVID-19 pandemic under their existing CLIA lab certificate. On March 27, 2020 AACC endorsed S.3512, the Verified Innovative Testing in American Laboratories (VITAL) Act, which would codify federal regulation of laboratory developed tests under the Clinical Laboratory Improvement Amendment regulations overseen by the Centers for Medicare and Medicaid Services.	Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE		70000	0	0	2020-04-08T10:55:21.433000-04:00